Guideline-directed medical therapies: Guideline-directed medical therapies for patients at risk of heart failure, including angiotensin converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB) , beta-blockers and sodium-glucose cotransporter 2 (SGLT2) inhibitors.
This multicenter retrospective study evaluates whether artificial intelligence-enabled electrocardiography (AI-ECG) can identify individuals at high risk for left ventricular dysfunction and whether targeted guideline-directed medical therapy can mitigate subsequent risk. Using a large multicenter cohort of patients with preserved left ventricular systolic function, the investigators applied an AI-ECG-based risk stratification approach and emulated a target trial to examine the association between guideline-directed therapies and the risk of incident left ventricular functional decline.
| Facility | City | Region | Status |
|---|---|---|---|
| Tri-Service General Hospital | Taipei | Taipei | Recruiting |
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07355023 on ClinicalTrials.gov ↗ ← All trials in Taiwan